WithdrawnNot applicableNCT00110006

Positron Emission Tomography Using Fludeoxyglucose F 18 in Predicting Response to Treatment in Patients Who Are Receiving Rituximab and Combination Chemotherapy for Newly Diagnosed Non-Hodgkin's Lymphoma

Studying Anaplastic large cell lymphoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Case Comprehensive Cancer Center
Principal Investigator
Panayiotis Savvides, MD
Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center
Intervention
rituximab(biological)
Eligibility
18 years · All sexes
Timeline
2004

Collaborators

National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00110006 on ClinicalTrials.gov

Other trials for Anaplastic large cell lymphoma

Additional recruiting or active studies for the same condition.

See all trials for Anaplastic large cell lymphoma →

← Back to all trials